Header Logo

Connection

Nancy Reau to Antiviral Agents

Back to Details
This is a "connection" page, showing publications Nancy Reau has written about Antiviral Agents.
Nancy Reau
Connection Strength
6.788
Antiviral Agents
  1. Report from the International Conference on Viral Hepatitis - 2017. AIDS Rev. 2018 Jan-Mar; 20(1):58-70.
    View in: PubMed
    Score: 0.560
  2. Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119.
    View in: PubMed
    Score: 0.535
  3. Generic medications for hepatitis C. Liver Int. 2016 07; 36(7):925-8.
    View in: PubMed
    Score: 0.505
  4. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Am J Gastroenterol. 2016 06; 111(6):845-51.
    View in: PubMed
    Score: 0.496
  5. HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver Int. 2016 Apr; 36(4):488-502.
    View in: PubMed
    Score: 0.484
  6. Sticker shock and the price of new therapies for hepatitis C: is it worth it? Hepatology. 2014 Apr; 59(4):1246-9.
    View in: PubMed
    Score: 0.429
  7. Naives, nonresponders, relapsers: who is there left to treat? Clin Liver Dis. 2011 Aug; 15(3):483-95.
    View in: PubMed
    Score: 0.359
  8. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb; 19(2):94-102.
    View in: PubMed
    Score: 0.345
  9. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 2011 Mar; 106(3):452-8.
    View in: PubMed
    Score: 0.341
  10. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008 Aug; 103(8):1981-8.
    View in: PubMed
    Score: 0.292
  11. Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019. Adv Ther. 2021 12; 38(12):5777-5790.
    View in: PubMed
    Score: 0.182
  12. Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy. J Hepatol. 2021 03; 74(3):734-741.
    View in: PubMed
    Score: 0.171
  13. Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C. Adv Ther. 2021 01; 38(1):423-440.
    View in: PubMed
    Score: 0.170
  14. Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis. Curr Med Res Opin. 2020 08; 36(8):1325-1332.
    View in: PubMed
    Score: 0.166
  15. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)". J Hepatol. 2020 03; 72(3):592-593.
    View in: PubMed
    Score: 0.161
  16. Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. J Gen Intern Med. 2020 04; 35(4):1011-1020.
    View in: PubMed
    Score: 0.159
  17. Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma. Dig Liver Dis. 2020 01; 52(1):98-101.
    View in: PubMed
    Score: 0.158
  18. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019 09; 71(3):486-497.
    View in: PubMed
    Score: 0.154
  19. A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908.
    View in: PubMed
    Score: 0.146
  20. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011.
    View in: PubMed
    Score: 0.141
  21. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018 05; 68(5):895-903.
    View in: PubMed
    Score: 0.139
  22. Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. Gastroenterology. 2017 05; 152(6):1588-1598.
    View in: PubMed
    Score: 0.134
  23. Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. Contemp Clin Trials. 2017 06; 57:58-68.
    View in: PubMed
    Score: 0.133
  24. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
    View in: PubMed
    Score: 0.121
  25. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
    View in: PubMed
    Score: 0.116
  26. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology. 2014 May; 59(5):1688-91.
    View in: PubMed
    Score: 0.107
  27. Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. Liver Int. 2021 04; 41(4):692-704.
    View in: PubMed
    Score: 0.043
  28. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States. Clin Infect Dis. 2019 11 13; 69(11):1888-1895.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.